Indication
Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1).
Loading your page…
Loading your page…
Cholestasis, Intrahepatic
Marketing Authorisation Holder: Ipsen Pharma
EMA Authorisation: 16/07/2021
INN: odevixibat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Bylvay: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.